PLK1 and ovarian serous adenocarcinoma: For instance, anti-EGFR-LNPs loaded with Cas9 mRNA and PLK1 sgRNA enabled ~82% of PLK1 gene editing in human serous ovarian adenocarcinomas Ovcar8 (OV8) cells, which strongly inhibited tumor growth and increased overall survival by ~80% in metastatic OV8-bearing mice (Rosenblum et al.2020).